期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Ⅱ和Ⅲ期乳腺癌新辅助化疗后术后放疗价值 被引量：4

原文传递
导出
摘要 早期浸润性乳腺癌保乳术后WBI可以降低2/3的LR率,在辅助全身治疗基础上的PMRT可以在中-高度复发风险的患者中降低60％～ 70％的5年LR率,并获得生存获益.NAC的运用已经从不可手术的局部晚期乳腺癌扩展至可手术乳腺癌,为患者提供了根治性切除或乳房保留的可能.由于NAC改变了初始乳腺癌的病理特征,让约20％～40％的NAC临床腋窝淋巴结阳性的患者转阴;在Her-2阳性患者,联合赫赛汀的NAC方案中更可使淋巴结转阴率达74％;在一定程度上降低了术后病理对放疗指征的指导价值,使得NAC后的辅助放疗的决策更复杂.
作者 徐菲 陈佳艺
机构地区 复旦大学上海医学院肿瘤学系复旦大学附属肿瘤医院肿瘤放疗科
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2014年第6期549-551,共3页 Chinese Journal of Radiation Oncology
关键词 Ⅲ期乳腺癌 术后放疗 价值 腋窝淋巴结阳性 化疗后 早期浸润性乳腺癌 可手术乳腺癌 局部晚期乳腺癌
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Darby S, Mcgale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials [J]. Lancet, 2011,378: 1707- 1716.
  • 2Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet,2005,366:2087-2106.
  • 3van der Hage JA,van de Velde C J, Julien J P, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 [ J]. J Clin Oncol,2001,19 :4224-4237.
  • 4Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [ J]. J Clin Oneol, 1999,17:460-469.
  • 5Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J]. J Clin Onco1,2006 ,24 :2019-2027.
  • 6Dominici LS, Negron GV, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2- positive breast cancer [ J ]. Cancer,2010,116:2884-2889.
  • 7Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local- regional recurrence after neoadjuvant chemotherapy and masteetomy without radiation [ J]. J Clin Oncol,2002,20 : 17-23.
  • 8Hoffman KE, Mittendorf EA, Buehholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and masteetomy [ J ]. Lancet Oncol, 2012,13 : 270- 276.
  • 9Huang EH,Tucker SL,Strom EA,et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy [ J ]. Int J Radiat Oncol Biol Phys,2005,62:351-357.
  • 10Mamounas EP, Anderson S J, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27 [J]. J Clin Oncol,2012,30:3960- 3966.

同被引文献24

引证文献4

二级引证文献20

中华放射肿瘤学杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部